Ali Abdelaziz

Dr. Ali Abdelaziz

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Clinical Hypertension
Verified
Journal Article
Open access
PDF file
ALAbdelaziz Louat
Abdelaziz Louat
MDMohammad Dwikat
Mohammad Dwikat
MNMohamedhen Vall Nounou
Mohamedhen Vall Nounou
SASalaheddin M. Abdulhamid
Salaheddin M. Abdulhamid
AAAli Abdelaziz
Ali Abdelaziz
MEMuhammed Elhadi
Muhammed Elhadi
Louat A, et al. Clin Hypertens. 2025 Dec;31:e41. https://doi.org/10.5646/ch.2025.31.e41

18 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PSPierre SABOURET
Pierre SABOURET
DGDomenico Mario Giamundo
Domenico Mario Giamundo
FCFrancesco Costa
Francesco Costa
PCPiera Capranzano
Piera Capranzano
LSLUIGI SPADAFORA
LUIGI SPADAFORA
Giuseppe AndòGiuseppe Andò
Giuseppe Andò
Arterial thrombosis emerges from the interplay between plaque disruption, platelet activation, and coagulation pathway amplification on a background of heterogeneous ischemic and bleeding risk. Optimal antithrombotic therapy therefore varies across clinical settings, from acute coronary syndromes (ACS) to chronic coronary syndromes (CCS), ischemic stroke, peripheral artery disease (PAD), and atrial fibrillation (AF) associated with atherosclerotic disease. Contemporary European and North American guidelines endorse an increasingly individualized approach, moving away from rigid “one-size-fits-all” dual antiplatelet therapy (DAPT) duration and intensity and incorporating dual pathway inhibition with low-dose rivaroxaban plus aspirin in selected high-risk CCS and PAD patients. In ischemic stroke, short-course DAPT is confined to minor events and transient ischemic attacks, whereas long-term monotherapy remains standard, and the coexistence of AF typically shifts the balance toward oral anticoagulation. Across all scenarios, antithrombotic benefit must be weighed against bleeding, especially in elderly, frail, or comorbid patients. Evidence gaps remain substantial, particularly in patients with overlapping vascular territories, AF plus atherosclerotic disease, and after ischemic stroke of complex or mixed mechanisms. This narrative review summarizes current evidence and guideline-based strategies in major atherosclerotic settings, proposes a unifying conceptual framework, and highlights key uncertainties and research directions for truly personalized antithrombotic care.

23 January 2026 in Cardiology
Verified
Journal Article
Open access
AAAlhasan Saleh Alzubi
Alhasan Saleh Alzubi
AAAli Abdelaziz
Ali Abdelaziz
MNMohamedhen Vall Nounou
Mohamedhen Vall Nounou
AAAbdelrahman Farag Abdelwahed
Abdelrahman Farag Abdelwahed
SPShane V. Perelman
Shane V. Perelman
ETEllen Thompson
Ellen Thompson
Introduction: Sex disparities in the clinical presentation, management, and outcomes of infective endocarditis (IE) remain inconsistent throughout the literature. We aimed to investigate the prognostic impact of sex-associated disparities in all-cause mortality and baseline clinical characteristics among patients with IE. Methods: We comprehensively searched PubMed, Scopus, Embase, and Web of Science till July 2025 for studies reporting sex-specific data on clinical presentation, mortality, and management patterns in IE. We reconstructed individual patient data from published Kaplan-Meier plots for all-cause mortality and estimated HR with 95% CI using a Cox regression model. Data regarding clinical presentation, microbiological profile, and management were pooled using random-effects meta-analysis. Results: Eighteen studies comprising 12,594 female and 24,365 male patients were included. Female sex was associated with a higher risk of mortality (HR: 1.338, 95% CI: 1.272–1.407, p < 0.001). Women more often had mitral valve endocarditis and valve vegetations but less frequently aortic valve endocarditis and intracardiac abscesses. Rates of surgical indication were similar between sexes, yet women underwent surgery less often, coinciding with higher baseline EuroScore II. Enterococcal infections were less common in women, with no significant sex differences for other microbiological etiologies. Conclusion: Women with IE experience higher mortality than men despite similar surgical indications, alongside distinctive valve involvement patterns, higher baseline surgical risk, and lower surgical intervention rates. Earlier recognition, timely intervention, and optimized surgical decision-making in women may help reduce this disparity.

20 February 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
AIAhmed Ibrahim
Ahmed Ibrahim
LSLaila Shalabi
Laila Shalabi
SZSofian Zreigh
Sofian Zreigh
SRShrouk Ramadan
Shrouk Ramadan
SMSohaila Mourad
Sohaila Mourad
MMMamas A. Mamas
Mamas A. Mamas

24 July 2026 in Structural Heart
Verified
Journal Article
Open access
AAAli Abdelaziz
Ali Abdelaziz
MNMohamedhen Vall Nounou
Mohamedhen Vall Nounou
AOAhmad Al Othman
Ahmad Al Othman
MAMirvat Alasnag
Mirvat Alasnag
ACAlaide Chieffo
Alaide Chieffo
MMMamas A. Mamas
Mamas A. Mamas

23 October 2025 in Cardiology
Verified
Journal Article
Open access
AKArwi Omar Kara
Arwi Omar Kara
MBMohammed S. Beshr
Mohammed S. Beshr
AAAli Abdelaziz
Ali Abdelaziz
AAAlhasan S. Alzubi
Alhasan S. Alzubi
AAArowa Hassan Abdulrahman Alansari
Arowa Hassan Abdulrahman Alansari
MMMamas A. Mamas
Mamas A. Mamas
Introduction: Transcatheter aortic valve implantation (TAVI) may be complicated by postoperative bleeding due to heparin use. Heparin antagonists, such as protamine, have shown potential in reducing bleeding risks. This meta-analysis assesses the efficacy and safety of protamine in reducing bleeding complications after TAVI. Methods: A systematic search was conducted up to March 2025. Inclusion criteria encompassed studies reporting the use of protamine post-TAVI with a control group. Primary outcomes included major bleeding events as the efficacy endpoint, 30-day mortality, and ischemic events (stroke and transient ischemic attack, or TIA) as safety endpoints. Secondary outcomes included life-threatening bleeding events and the need for blood transfusion. A random-effects model was used to calculate odds ratios (ORs). Results: Four studies involving 1,569 patients were included. As compared to the control group, protamine was not associated with a statistically significant difference in major bleeding events (OR = 0.59, 95% CI = 0.26–1.34, p = 0.21), life-threatening bleeding events (OR = 0.3, 95% CI = 0.06–1.62, p = 0.16), need for blood transfusions (OR = 0.75, 95% CI = 0.46–1.24, p = 0.27), 30-day mortality (OR = 1.07, 95% CI = 0.54–2.11, p = 0.85), or rate of stroke and TIA (OR = 0.86, 95% CI = 0.05–13.58, p = 0.91). Conclusion: Protamine use after TAVI appeared to be safe with no increase in 30-day mortality or stroke and TIA rates, but there was no observed statistically significant benefit in the reduction of major or life-threatening bleeding events and the need for blood transfusions. These findings are based on a limited number of studies, and larger randomized controlled trials are warranted to confirm them.